Nature Communications (Dec 2021)
Intermittent BRAF inhibition in advanced BRAF mutated melanoma results of a phase II randomized trial
- Maria Gonzalez-Cao,
- Clara Mayo de las Casas,
- Juana Oramas,
- Miguel A. Berciano-Guerrero,
- Luis de la Cruz,
- Pablo Cerezuela,
- Ana Arance,
- Eva Muñoz-Couselo,
- Enrique Espinosa,
- Teresa Puertolas,
- Roberto Diaz Beveridge,
- Sebastian Ochenduszko,
- Maria-Jose Villanueva,
- Laura Basterretxea,
- Lorena Bellido,
- Delvys Rodriguez,
- Begoña Campos,
- Clara Montagut,
- Ana Drozdowskyj,
- Miguel A. Molina,
- Jose Antonio Lopez-Martin,
- Alfonso Berrocal
Affiliations
- Maria Gonzalez-Cao
- Translational Cancer Research Unit, Instituto Oncologico Dr Rosell, Dexeus University Hospital
- Clara Mayo de las Casas
- Translational Cancer Research Unit, Instituto Oncologico Dr Rosell, Dexeus University Hospital
- Juana Oramas
- Hospital Universitario de Canarias
- Miguel A. Berciano-Guerrero
- Hospitales Universitarios Regional y Virgen de la Victoria (HURyVV). Instituto de Investigaciones Biomédicas de Málaga (IBIMA)
- Luis de la Cruz
- Hospital Universitario Virgen Macarena
- Pablo Cerezuela
- Hospital Clínico Universitario Virgen de la Arrixaca
- Ana Arance
- Hospital Clinic
- Eva Muñoz-Couselo
- Hospital Valle Hebron
- Enrique Espinosa
- Hospital Universitario la Paz, CIBERONC
- Teresa Puertolas
- Hospital Miguel Servet
- Roberto Diaz Beveridge
- Hospital Universitario la Fe
- Sebastian Ochenduszko
- Hospital Universitario Dr Peset
- Maria-Jose Villanueva
- Hospital de Vigo
- Laura Basterretxea
- Hospital Universitario de Donostia
- Lorena Bellido
- Hospital Universitario de Salamanca
- Delvys Rodriguez
- Hospital Insular Las Palmas
- Begoña Campos
- Hospital Lucus Agusti
- Clara Montagut
- Hospital del Mar, IMIM, CIBERONC
- Ana Drozdowskyj
- Translational Cancer Research Unit, Instituto Oncologico Dr Rosell, Dexeus University Hospital
- Miguel A. Molina
- Translational Cancer Research Unit, Instituto Oncologico Dr Rosell, Dexeus University Hospital
- Jose Antonio Lopez-Martin
- Hospital 12 de Octubre
- Alfonso Berrocal
- Hospital General de Valencia
- DOI
- https://doi.org/10.1038/s41467-021-26572-6
- Journal volume & issue
-
Vol. 12,
no. 1
pp. 1 – 6
Abstract
Whether intermittent strategies of delivering drugs can improve cancer patients survival is still unclear. Here, the authors reports the results of a randomized phase II clinical trial aimed to compare the efficacy and safety of two dosing regimens (continuous and intermittent) of vemurafenib and cobimetinib combination as first-line treatment of patients with unresectable or metastatic advanced melanoma with BRAFV600 mutation
